goeke02
Posted - 2 days ago
$QDEL I was so pissed when I sold this in the 160s for a huge loss and now it was just a blessing to take the loss. What a POS this has become. 7 year lows. I honestly might have to get back in if it goes in the 20s.
Tryingnottolosemyarse
Posted - 1 week ago
$QDEL Jesus every day is a new 52 week low.
RedBear
Posted - 1 week ago
$QDEL you know where to get the rest of the chart. thanks for supporting me. seeing some key levels to make your money back.
East161stNY
Posted - 1 week ago
$QDEL now below 40!
Stock_Titan
Posted - 1 week ago
$QDEL QuidelOrtho To Report First Quarter 2024 Financial Results
https://www.stocktitan.net/news/QDEL/quidel-ortho-to-report-first-quarter-2024-financial-hsgjf6l3c84f.html
East161stNY
Posted - 1 week ago
$QDEL QDELQ
Stan_Vick
Posted - 1 week ago
QuidelOrtho investor filed claim vs $QDEL for hiding overstocking and prospects for RVP4 in US. In April, withdrawn FDA submission caused $QDEL to fall 10% losing $324M shareholder value. You can join case to be notified about potential recovery here => https://11thestate.com/cases/quidel-investor-suit
Stocksrunner
Posted - 1 week ago
Saturday Stock Market Recap $QDEL - Attractive valuation despite weak performance. $SPHD - High dividend, but better options available. $RXT - Rackspace Technology announces final results of its debt exchange offer. $TSLA - Tesla cut the price of its FSD service, impacting the stock. Stay tuned for more market updates. Have a great weekend!
Staska
Posted - 2 weeks ago
$QDEL QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay (“MPA”). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decision. https://ir.quidelortho.com/news/news-release-details/2024/QuidelOrtho-Adds-Fentanyl-Test-to-Its-Vitros-Systems-as-a-MicroTip-Partnership-Assay/default.aspx
Stock_Titan
Posted - 2 weeks ago
$QDEL QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
https://www.stocktitan.net/news/QDEL/quidel-ortho-adds-fentanyl-test-to-its-vitros-r-systems-as-a-micro-k810l518gw2t.html
DonCorleone77
Posted - 3 weeks ago
$QDEL Really??? I thought the 10% drop today was due to investor confidence :o) QuidelOrtho news does not help investor sentiment, says William Blair William Blair says QuidelOrtho's decision withdraw the current FDA 510(k) submission for the Savanna RVP4+ assay is disappointing and does not help improve sentiment on the shares. The firm is "not all that surprised" to see the stock trading down high-single-digits following the news. While there is little in the stock in terms of valuation for Savanna, this is a required assay to help drive a meaningful number of platform placements, the analyst tells investors in a research note. Blair says the test's clearance is ow less likely to come later this year, and with competitors like bioMerieux and its Spotfire platform extending its respiratory menu by recently obtaining 510(k) clearance, "this is critical time that is potentially lost" for QuidelOrtho. The firm keeps a Market Perform rating on the shares.
I_hate_intel
Posted - 3 weeks ago
$QDEL just wow, too cheap. I added a bunch at 42.
EquiStar
Posted - 3 weeks ago
$QDEL ....sold today....and took a loss. 40% ...that is my rule so must follow it. If they make progress I might get back in but obviously company needs to cut cost and the news this morning was icing on the cake. Investing rules must be followed.
ballerallday
Posted - 3 weeks ago
$QDEL growth evaporating. Headed towards the $20s.
DonCorleone77
Posted - 3 weeks ago
$QDEL QuidelOrtho down nearly 9% after withdrawing submission for RVP4+ assay
gvnbykplt1903
Posted - 3 weeks ago
$QDEL I have 100 shares average $76 . I m not averaging down anymore. Also not selling under $100 . I would only sell if it is $100 or if zoom stock fall same price with qdel and then I would switch qdel to zoom. This is fucking ridiculous.
Staska
Posted - 3 weeks ago
$QDEL That's not good. QuidelOrtho is committed to building the Savanna menu with the highest quality assays. As a result, upon reviewing the performance of the Savanna RVP4+ assay against the clinical market’s expectations, a decision was made to withdraw the current FDA 510(k) submission for the Savanna RVP4+ assay. Data generated over a 9-month period for the four viruses targeted by the assay initially showed great promise, which led to the FDA submission in July 2023. However, the final dataset, submitted in February 2024, did not meet our expectations. In addition, during the pendency of the submission, the Company has continued to develop the next-generation RVP4+ assay. The Company anticipates the new multiplex assay to be commercially available during the 2024/2025 respiratory season.
https://ir.quidelortho.com/news/news-release-details/2024/QuidelOrtho-Receives-FDA-510k-Clearance-for-Its-QuickVue-COVID-19-Test/default.aspx
UsandThem7
Posted - 3 weeks ago
$QDEL covid test? These idiots are wasting their time and shareholder resources.
Stock_Titan
Posted - 3 weeks ago
$QDEL QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
https://www.stocktitan.net/news/QDEL/quidel-ortho-receives-fda-510-k-clearance-for-its-quick-vue-r-covid-39macxwi6ur1.html
Staska
Posted - 03/28/24
$QDEL
I think the real reason why Douglas Bryant got fired is Savanna RVP4 approval, on January 8th this year Douglas Bryant then CEO said on J.P. Morgan Healthcare Conference, that he COMMITS that Savanna RVP4 will be approved by the end of first quarter. And it's clearly not happening. Interim CEO Michael Iskra recently said on Raymond James Conference that they hope to get approval by the end of this year... I don't know what's happening with Savanna RVP4, but there is a reason why QDEL are not getting approval, and it's annoying!
UncleStock
Posted - 03/27/24
$SMLR $FLGT $IRMD $QDEL suggested for Medical Equipment and Services - value screen: https://zpr.io/58kdvfpRwWhn
UncleStock
Posted - 1 month ago
$SMLR $FLGT $IRMD $QDEL suggested for Medical Equipment and Services - value screen: https://zpr.io/58kdvfpRwWhn
UncleStock
Posted - 1 month ago
$SMLR $FLGT $IRMD $QDEL suggested for Medical Equipment and Services - value screen: https://zpr.io/58kdvfpRwWhn
Staska
Posted - 1 month ago
$QDEL
Spring may be around the corner but the flu – specifically, influenza B – is surging.
While samples of influenza A have decreased since the winter-time peak, influenza B has been detected in 96% of samples, so far, in March compared with 66% of samples in February, according to WastewaterSCAN data.
While it’s normal for influenza A and B to peak at different times during the year, Wolfe noted that influenza B was nearly nonexistent last year.
The reappearance of this influenza B peak suggests common viruses in the U.S. may be returning to a more reliable, seasonal pattern, Wolfe said. https://eu.usatoday.com/story/news/health/2024/03/18/flu-norovirus-spring-illness-season/72955104007/
Staska
Posted - 1 month ago
$QDEL
https://www.marketbeat.com/instant-alerts/nasdaq-qdel-options-data-report-2024-03-13/
Staska
Posted - 1 month ago
$QDEL
Iskra, at the investor conference last week, said “less than 10%” of the company’s workforce would be impacted by the headcount reduction plan, as the company expands the scope of its cost-savings initiative. He also said the company was moving quickly to complete the plan.
“The headcount opportunity, I think we looked to have completed by the end of Q2. In the last week and a half, we’ve accelerated that timeline. We’ve increased the target that we’re going to go after,” Iskra said.
The company was focused on cost savings initiatives to address inflation challenges, improve merger synergies and position the company to take advantage of growth opportunities.
“Coming out of Q4 into Q1, there’s a lot of effort underway for margin restoration,”
https://www.medtechdive.com/news/quidelortho-lay-off-less-than-10-of-staff-interim-ceo-says/710315/?utm_campaign=Yahoo-Licensed-Content&utm_source=yahoo&utm_medium=newsfeed
UncleStock
Posted - 1 month ago
$SMLR $FLGT $IRMD $QDEL suggested for Medical Equipment and Services - value screen: https://zpr.io/58kdvfpRwWhn
Staska
Posted - 1 month ago
$QDEL
Per a report by Transparency Market Research, the global pre-eclampsia diagnostics market was valued at $1.5 billion in 2021 and is anticipated to reach $2.3 billion by 2031 at a CAGR of approximately 3.8%. Factors like the increasing incidence of pre-eclampsia and the growing prevalence of lifestyle diseases are likely to drive the market.Given the market potential, the latest regulatory clearance will likely provide a significant impetus to QuidelOrtho’s business.
www.zacks.com/amp/stock/news/2237410/quidelorthos-qdel-new-approval-to-aid-pre-eclampsia-diagnosis
Staska
Posted - 1 month ago
$QDEL The Triage PLGF test delivers results in approximately 15 minutes and provides high accuracy to support the clinical diagnosis of pre-eclampsia needing delivery within 14 days. When integrated into a clinical management guideline, the Triage PLGF test can lead to faster diagnosis and a 20% reduction in maternal adverse outcomes.5 The Triage PLGF test is unique because it measures a single biomarker on the Triage MeterPro instrument, unlike other tests which require two biomarkers measured on a larger-footprint laboratory analyzer. The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument. The Triage MeterPro instrument is easy to use with robust quality control and would be suitable for urban and rural laboratory settings, delivering Triage PLGF test results quickly. https://ir.quidelortho.com/news/news-release-details/2024/QuidelOrtho-Receives-Health-Canada-Approval-for-Quidel-Triage-PLGF-Test-for-Laboratory-Use-in-Canada/default.aspx